logo
Walmart recalls shrimp possibly exposed to radioactive material

Walmart recalls shrimp possibly exposed to radioactive material

Yahoo6 hours ago
Walmart has recalled some shrimp products in 13 US states after one shipment of seafood tested positive for radioactive contamination.
The US Food and Drug Administration said varieties of frozen shrimp sold under Walmart's Great Value label could have been exposed to a dangerous isotope in shipping containers.
One sample of breaded shrimp tested positive for the substance, but this positive sample "did not enter US commerce", the FDA said.
Consumers are advised to throw away recently bought Walmart shrimp that matches this description - and not to eat or serve it.
"The health and safety of our customers is always a top priority," a Walmart spokesperson told the BBC. "We have issued a sales restriction and removed this product from our impacted stores. We are working with the supplier to investigate."
The spokesperson added that consumers who bought the recalled products can visit any Walmart location for a full refund.
The recalled shrimp was sold at Walmart locations in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia, and shoppers in those states were advised to be cautious.
It came from an Indonesian supplier that has since had multiple shipping containers denied entry to the US, the FDA said.
One shipment tested positive for Cesium-137, the radioactive form of the chemical element Cesium.
The amount contained in the tested shipment held by the FDA was not enough to pose acute harm to consumers, but exposure over time could pose an elevated risk of cancer by damaging living cells in the body, said FDA officials.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The Walmart Frozen Shrimp Subject To Recall Due To Potential Radioactive Risks
The Walmart Frozen Shrimp Subject To Recall Due To Potential Radioactive Risks

Yahoo

timean hour ago

  • Yahoo

The Walmart Frozen Shrimp Subject To Recall Due To Potential Radioactive Risks

The Food and Drug Administration (FDA) has protocols in place to detect contaminated foods before they enter the country. And, as of today, it has advised the public not to eat specific Great Value brand frozen raw shrimp sold in Walmart stores due to a possible radioactive risk. During regular inspections, the U.S. Customs & Border Protection (CBP) detected Cesium-137 (Cs-137) in a single sample of breaded shrimp, and all related containers and products were prevented from entering the United States. Cs-137 is a manmade radioisotope of cesium that's so widespread that it can be found in the air, soil, and food. After the FDA was alerted to the presence of this chemical, its own testing found about 68.48 Bq/kg — much lower than the 1200 Bq/kg threshold — in the breaded product (per the FDA advisory). Although the chemical wasn't found in other products tested, the agency says some could still be contaminated, representing a potential health concern but not an acute hazard. Since the investigation is ongoing, it's unclear if this frozen shrimp will become one of the worst seafood recalls that swept across America or even be among the biggest Walmart Great Value brand recalls in history. Read more: 14 Canned Foods To Stock Up On Before They Go Up In Price Specific Products Affected And What To Do The convenience and versatility of frozen shrimp make it a staple for many households. When you're looking for high-quality frozen shrimp to buy, though, reading the package label and looking for quality characteristics won't always protect you when some kind of contamination has occurred. The 2-pound bags of Great Value Raw Ez Peel Tail-On Farm-Raised White Vannamei Shrimp that the FDA is concerned about are processed by PT. Bahari Makmur Sejati, an Indonesian company that does business as BMS Foods. The lot codes are 8005540-1, 8005538-1, and 8005539-1 — all with a Best by Date of March 15, 2027. Exposure to possible low-level radiation from Cs-137 in these products could impact consumers' health with prolonged exposure. Because of that, the FDA suggests that customers who have purchased any of these packages throw them away; do not eat or serve them. It also advises that customers contact their healthcare teams if they have already eaten these products and experience adverse symptoms. Meanwhile, the FDA has recommended that Walmart issue a recall and that all distributors and retailers not sell or serve the products. Hungry for more? Sign up for the free Daily Meal newsletter for delicious recipes, cooking tips, kitchen hacks, and more, delivered straight to your inbox. Read the original article on The Daily Meal. Solve the daily Crossword

MBX Biosciences Submits IND for Once-Monthly Obesity Drug
MBX Biosciences Submits IND for Once-Monthly Obesity Drug

Yahoo

time2 hours ago

  • Yahoo

MBX Biosciences Submits IND for Once-Monthly Obesity Drug

MBX Biosciences Inc. (NASDAQ:MBX) is one of the best IPO stocks to buy according to Wall Street analysts. On June 16, MBX Biosciences announced the submission of an Investigational New Drug/IND application to the US FDA for MBX 4291. This drug is a long-acting GLP-1/GIP receptor co-agonist prodrug being developed for the treatment of obesity. The company's President and CEO, Kent Hawryluk, stated that MBX 4291 is designed to be a potential once-monthly injectable, which could offer less frequent dosing and improved gastrointestinal tolerability, potentially leading to better patient adherence and increased weight loss. MBX 4291 was created using the company's proprietary Precision Endocrine Peptide/PEP platform. A doctor holding a test tube of the biopharmaceutical company's NicAlert drug product while providing patient care. In preclinical studies, the active component of MBX 4291 demonstrated a similar activity profile and body weight loss as tirzepatide, a weekly GLP-1/GIP co-agonist that is already approved. Furthermore, these preclinical studies showed an extended duration of action for MBX 4291's active component compared to tirzepatide, supporting the potential for once-monthly administration. MBX Biosciences Inc. (NASDAQ:MBX) is a clinical-stage biopharmaceutical company that discovers and develops precision peptide therapies for the treatment of endocrine and metabolic disorders. While we acknowledge the potential of MBX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Ozempic creator Novo Nordisk will sell weight loss drugs for cheaper through this new partnership
Ozempic creator Novo Nordisk will sell weight loss drugs for cheaper through this new partnership

Yahoo

time3 hours ago

  • Yahoo

Ozempic creator Novo Nordisk will sell weight loss drugs for cheaper through this new partnership

Ozempic creator Novo Nordisk will sell weight loss drugs for cheaper through this new partnership originally appeared on TheStreet. Telemedicine company GoodRx () has been helping Americans find the cheapest way to buy drugs for years. Thanks to a new partnership with pharma giant Novo Nordisk () , the creator of Ozempic and Wegovy, it might soon be the cheapest way to buy branded weight loss drugs too. On Monday, the two firms announced a partnership which will allow patients with a prescription to get the branded medication for $499/mo, so long as they're willing to pay out of pocket and present the GoodRx coupon at their local pharmacy. At $499/mo the branded drug is only a little more expensive than compounded GLP-1 injectables sold by telehealth pharmacies, which have drawn the ire of pharmaceutical giants and the Food and Drug Administration (FDA). It's also more expensive than the $349/mo single-dose vial of Zepbound, the competing GLP-1 drug sold by competitor Eli Lilly () , which is also available through GoodRx. However, Ozempic and Wegovy's patented pens might be reason enough to pay up, since they're easier to use. Still, those with insurance might be eligible to have the cost completely covered, rather than pay the out of pocket cost. For that, patients should check with their prescriber and insurer. This is not Novo's first ride on the direct-to-consumer wagon. In April, it partnered with Hims & Hers HIMS (-1%) to help them sell Wegovy directly to customers. Novo ended that effort in July, alleging that the telehealth company intentionally undercut their branded medications through "deceptive promotion and selling of illegitimate, knockoff versions" of its drug, which "put patient safety at risk." A lawsuit has been filed against Hims & Hers. The failed "collaboration" between the companies spurred the departure of its chief executive, as well as a reduction to the company's annual guidance ahead of its quarterly earnings. Worst of all, it say Novo Nordisk lose market share to competitor Eli Lilly, which represents over half of the GLP-1 market. Novo's leadership have indicated a desire to expand its direct-to-consumer offerings and cut prices, looking to undercut both branded and compounded GLP-1 drugs. Ozempic creator Novo Nordisk will sell weight loss drugs for cheaper through this new partnership first appeared on TheStreet on Aug 18, 2025 This story was originally reported by TheStreet on Aug 18, 2025, where it first appeared.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store